Perrigo Reaches 5-Day High Amid Class Action Lawsuit News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy PRGO?
Source: Globenewswire
Perrigo Company PLC's stock rose by 5.02%, reaching a 5-day high. This increase comes despite broader market declines, with the Nasdaq-100 down 0.31% and the S&P 500 down 0.37%.
The rise in Perrigo's stock is linked to recent news regarding a class action lawsuit filed against the company for allegedly misleading investors about its financial health and operational issues following its acquisition of Nestlé's infant formula business. The lawsuit claims that Perrigo failed to disclose significant underinvestment and manufacturing deficiencies, which has raised concerns among investors.
This legal challenge could have implications for Perrigo's reputation and financial stability, as investors seek damages for losses incurred during the period in question. The outcome of the lawsuit may influence future investor confidence and stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 10.290
Low
18.00
Averages
20.33
High
23.00
Current: 10.290
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Small Caps Rebound with Yields Up to 11%
- Strong Small Cap Performance: Small caps have shown impressive performance in 2026, attracting investor interest due to their relatively cheap valuations despite risks of economic turbulence, which is expected to continue driving the market forward.
- Washington Trust Bancorp Yield: Washington Trust Bancorp (WASH) offers a dividend yield of 6.6%, achieving a 27% earnings growth in 2025, with a price-to-earnings ratio of just 10 times, highlighting its competitiveness in the financial sector.
- Diversified Energy Company Dynamics: Diversified Energy Company (DEC) attracts investors with an 8% dividend yield; although its growth potential is limited, it maintains stable cash flow and dividend payments through the acquisition of long-life assets.
- HR Company Outlook: Insperity (NSP) provides an 11% dividend yield, facing challenges with declining profits, yet its revenue continues to grow, with potential for business transformation through a new platform.
See More
Perrigo CEO to Present at UBS Conference
- Conference Schedule: Perrigo's CEO Patrick Lockwood-Taylor is set to present at the UBS Global Consumer and Retail Conference on March 11, 2026, at 11:00 AM EDT, highlighting the company's leadership in consumer health.
- Webcast Access: Interested parties can access the conference webcast via Perrigo's official website, ensuring that investors and the public can stay updated on the company's latest developments and strategic direction.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience, focusing on high-quality health and wellness solutions primarily for North America and Europe, emphasizing accessibility in over-the-counter self-care products.
- Business Model: Perrigo's unique business model leverages cash-generative private label offerings to fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, showcasing its competitive advantage in the market.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
- Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
- Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
See More
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
See More
Perrigo Company Q4 2025 Earnings Call Insights
- Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
- Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
- Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
- Cautious Future Outlook: Management anticipates 2026 to be a
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Small Caps Rebound with Yields Up to 11%
- Strong Small Cap Performance: Small caps have shown impressive performance in 2026, attracting investor interest due to their relatively cheap valuations despite risks of economic turbulence, which is expected to continue driving the market forward.
- Washington Trust Bancorp Yield: Washington Trust Bancorp (WASH) offers a dividend yield of 6.6%, achieving a 27% earnings growth in 2025, with a price-to-earnings ratio of just 10 times, highlighting its competitiveness in the financial sector.
- Diversified Energy Company Dynamics: Diversified Energy Company (DEC) attracts investors with an 8% dividend yield; although its growth potential is limited, it maintains stable cash flow and dividend payments through the acquisition of long-life assets.
- HR Company Outlook: Insperity (NSP) provides an 11% dividend yield, facing challenges with declining profits, yet its revenue continues to grow, with potential for business transformation through a new platform.
See More
Perrigo CEO to Present at UBS Conference
- Conference Schedule: Perrigo's CEO Patrick Lockwood-Taylor is set to present at the UBS Global Consumer and Retail Conference on March 11, 2026, at 11:00 AM EDT, highlighting the company's leadership in consumer health.
- Webcast Access: Interested parties can access the conference webcast via Perrigo's official website, ensuring that investors and the public can stay updated on the company's latest developments and strategic direction.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience, focusing on high-quality health and wellness solutions primarily for North America and Europe, emphasizing accessibility in over-the-counter self-care products.
- Business Model: Perrigo's unique business model leverages cash-generative private label offerings to fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, showcasing its competitive advantage in the market.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
- Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
- Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
See More
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
See More
Perrigo Company Q4 2025 Earnings Call Insights
- Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
- Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
- Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
- Cautious Future Outlook: Management anticipates 2026 to be a
See More
